Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Roy S. Herbst, MD, PhD

Lenvatinib/Pembrolizumab/Chemo Induces Inferior OS vs Pembrolizumab/Chemo in Previously Untreated NSCLC

January 5th 2024

Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.

Martin Wermke, MD

Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma

January 5th 2024

Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.

Melanoma - stock.adobe.com

Oncolytic Adenovirus TILT-123 Combined With TIL Therapy Is Safe in Metastatic Melanoma

January 5th 2024

Intravenous and intratumoral treatment with TILT-123 was found to be safe and feasible, with no dose-limiting toxicities when given alone or in combination with tumor infiltrating lymphocyte therapy in patients with advanced, metastatic melanoma.

Natasha B. Leighl, MD, BSc, MMSc

Lenvatinib Plus Pembrolizumab Fails to Improve OS and PFS Over Docetaxel in Stage IV NSCLC

January 4th 2024

Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

Niels Reinmuth, MD, PhD

LUMINANCE Data Support the Frontline Use of Durvalumab Plus Platinum/Etoposide in ES-SCLC

January 4th 2024

The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.

Benjamin Besse, MD, PhD, of Paris Saclay University at the Institut Gustave Roussy in Villejuif, France

Adjuvant Pembrolizumab Provides Sustained DFS Benefit in Resected Stage IB, II, or IIIA NSCLC

January 4th 2024

Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.

Solange Peters, MD, PhD

POSEIDON Update Confirms OS Benefit of Tremelimumab/Durvalumab Plus Chemo in mNSCLC

January 3rd 2024

A limited course of tremelimumab added to frontline durvalumab and chemotherapy provided a sustained overall survival benefit vs chemotherapy alone in patients with previously untreated metastatic non­–small cell lung cancer.

Scot Ebbinghaus, MD

Vibostolimab Plus Pembrolizumab Coformulation ± Docetaxel Did Not Significantly Improve PFS in NSCLC

January 3rd 2024

A coformulation of vibostolimab and pembrolizumab with or without docetaxel failed to result in a statistically significant improvement in progression-free survival compared with docetaxel alone in patients with metastatic non­–small cell lung cancer.

Akshat Jain, MBBS

Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding Disorders

December 15th 2023

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Zanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)

Zanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)

December 15th 2023

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

Jennifer Brown, MD, PhD

Acquired BTK and PLCG2 Mutations May Not Drive Progression After Zanubrutinib/Ibrutinib Treatment in Relapsed CLL

December 14th 2023

The majority of patients with relapsed CLL treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation at the time of disease progression, indicating that these mutations may not be the primary drivers of resistance and relapse in this population.

Jennifer Brown, MD, PhD

Responses With Pirtobrutinib Remain High Despite Acquired Resistance in Relapsed CLL/SLL

December 13th 2023

Responses on the non-covalent BTK inhibitor pirtobrutinib remained high in patients with relapsed chronic lymphocytic leukemia who expressed frequent baseline BTK mutations, according to a genomic analysis of the phase 1/2 BRUIN trial.

DZD8586 Produces Responses in B-Cell Non-Hodgkin Lymphoma

DZD8586 Demonstrates Responses Across Dose Levels in B-Cell Non-Hodgkin Lymphoma

December 13th 2023

DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.

Asciminib Elicits Safe and Durable Responses in Previously Treated CML

Asciminib Elicits Safe and Durable Responses in Previously Treated CML

December 12th 2023

Treatment with asciminib elicited greater efficacy and had a more tolerable safety profile compared with bosutinib for patients chronic myeloid leukemia in chronic phase following treatment with 2 or more TKIs.

Elizabeth K. O’Donnell, MD

Isa-KRd Produces Deep, Durable Response Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

December 12th 2023

The addition of isatuximab-irfc to carfilzomib, lenalidomide, and dexamethasone was well tolerated and elicited a 100% objective response rate in standard- and high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.

Allison J. Moskowitz, MD

Acimtamig Plus Allogeneic Natural Killer Cells Under Phase 2 Evaluation in R/R Hodgkin Lymphoma and CD30+ PTCL

December 12th 2023

Following promising preclincial findings, acimtamig plus allogenic natural killer cells will be examined for the treatment of patients with relapsed/refractory Hodgkin lymphoma and CD30-positive peripheral T-cell lymphoma.

Julio Chavez, MD, MS

Axi-Cel Provides Sustained Response in High-Risk Large B-cell Lymphoma

December 12th 2023

Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial.

Jason Westin, MD, MS, FACP

Tafasitamab Quadruplet Shows Efficacy in Newly Diagnosed DLBCL

December 12th 2023

The use of tafasitamab-cxix, lenalidomide, rituximab, and acalabrutinib in the first-line setting induced high responses in patients with newly diagnosed diffuse large B-cell lymphoma, with responders deriving benefit from subsequent treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone.

Jonathon B. Cohen, MD, MS

Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy

December 12th 2023

Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.

Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple Myeloma

Dr Matous on the Use Talquetamab/Pomalidomide in Relapsed/Refractory Multiple Myeloma

December 12th 2023

Jeffrey Matous, MD, discusses outcomes from the phase 1b MonumenTAL-2 trial with the combination of talquetamab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Jonathon B. Cohen, MD, MS

Dr Cohen on the Efficacy of Pirtobrutinib in High-Risk Patients With MCL

December 12th 2023

Jonathon B. Cohen, MD, MS, discusses safety and efficacy outcomes with pirtobrutinib in previously treated patients with relapsed/refractory mantle cell lymphoma, as observed in the phase 1/2 BRUIN study.

John F. Seymour, MBBS, PhD

BGB-16673 Delivers Responses With a Tolerable Safety Profile Across R/R B-Cell Malignancies

December 12th 2023

The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.

Ibrahim Aldoss, MD, of City of Hope

Revumenib Elicits High Response Rate in R/R KMT2A-Rearranged Acute Leukemia

December 12th 2023

Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.

Pieter Sonneveld, MD

D-VRd Improves PFS in Newly Diagnosed, Transplant-Eligible Multiple Myeloma

December 12th 2023

Induction therapy with subcutaneous daratumumab followed by autologous stem cell transplant, daratumumab, bortezomib, lenalidomide, and dexamethasone consolidation and daratumumab/lenalidomide maintenance prolonged progression-free survival in patients with newly diagnosed, transplant-eligible multiple myeloma.

Michael Wang, MD

Ibrutinib Plus Venetoclax Confers PFS, Response Benefit in Relapsed/Refractory MCL

December 12th 2023

Treatment with the oral BTK inhibitor ibrutinib in combination with venetoclax led to a statistically significant improvement in progression-free survival vs ibrutinib plus placebo in patients with relapsed/refractory MCL.

Mia Djulbegovic, MD, MS.

Financial Navigation Program May Alleviate Cost Burden Associated With Multiple Myeloma

December 12th 2023

Utilization of a financial navigation program is feasible for reducing cost burden and improving quality of life in patients with multiple myeloma who are more likely to experience financial toxicity and have difficulty accessing appropriate resources and support services.

Matthew Frigault, MD

Anito-Cel Elicits Responses With Manageable Safety in Relapsed/Refractory Multiple Myeloma

December 12th 2023

Anitocabtagene autoleucel showcased early efficacy with acceptable toxicity in patients with relapsed and/or refractory multiple myeloma—even in those with high-risk features.

Ajai Chari, MD

Talquetamab Dose Modifications May Lower AEs While Maintaining Efficacy in R/R Multiple Myeloma

December 12th 2023

Dose modifications of talquetamab improved on-target adverse effects while maintaining responses for patients with relapsed/refractory multiple myeloma.

Alexey Danilov, MD, PhD, of City of Hope

NX-2127 Elicits Responses With Manageable Safety in Heavily Pretreated B-cell Malignancies

December 12th 2023

NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.